cagrilintide semaglutide phase 2 weight loss Updates in Medicine | 🔬 REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio 👥 3a RCT in 1206 adults with T2D (BMI ≥27, HbA1c 7–10%) 💉 In the REDEFINE 2 phase

In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect cagrisema is one of the most #potent #weightloss medication developed till date! Cagrisema on an average causes 9% additional weight loss over # semaglutide 2.4mg week! Cagrisema is a fixed dose combination of semaglutide 2.4mg + #

SKU: 33665880468 · From equiscorp.hu